Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daptomycin versus active comparator for pediatric acute hematogenous osteomyelitis
2013-000864-28Phase 3Completed
- Sponsor
- Cubist Pharmaceuticals, Inc.
- Start
- Sep 2013
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of daptomycin in acute haematogenous osteomyelitis (AHO) (2 arms), sponsored by Cubist Pharmaceuticals, Inc. Primary endpoint: Clinical improvement by Day 5. Started Sep 2013; status: completed.
02
Drugs
daptomycin
03
Conditions
acute haematogenous osteomyelitis (AHO)
Beyond the preview
Go deeper on 2013-000864-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000864-28.